Rate Video

ASH 2018 | Updates from ASH 2018 in MDS therapy

Guillermo Garcia-Manero

ASH 2018

Myelodysplastic Syndromes Azacitidine Checkpoint inhibitors Guadecitabine Ipilimumab Pembrolizumab

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives his take on the highlights for myelodysplastic syndrome (MDS) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Pracinostat for AML update: follow-up analysis and Phase III trial

Guillermo Garcia-Manero • 9 Dec 2017

MRD Focus: why measurable residual disease testing is the future

Bruno Paiva et al.

TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS

Guillermo Garcia-Manero • 10 Jun 2022

May the force be with you: the power of next-generation sequencing

Guillermo Garcia-Manero • 9 Dec 2017

Related Videos

Somatic mutations in MDS as targets for therapy

Valeria Santini

Somatic mutations in MDS as a diagnostic and prognostic tool

Valeria Santini

A personalized prediction model to risk stratify patients with MDS

MDS news from ASH 2018